Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 long-term extension of elsubrutinib and upadacitinib in systemic lupus erythematosus
NL-OMON49547Phase 2Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elsubrutinib, upadacitinib and ABBV-599 in systemic lupus erythematosus (SLE) (4 arms), sponsored by AbbVie Inc. Planned start Sep 2020; status: withdrawn.
02
Drugs
elsubrutinibupadacitinibABBV-599
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON49547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49547.